Alere makes last pitch to shareholders; Cernostics hauls in $1.4M for cancer test;

@FierceMedDev: ICYMI Friday: Abiomed swings to loss on legal costs. Story | Follow @FierceMedDev

@MarkHFierce: ConforMIS, armed with $167.7M expanded series E, plots global marketing expansion. Report | Follow @MarkHFierce

@DamianFierce: Gore prevailed over St. Jude in a patent lawsuit over heart plugs. News | Follow @DamianFierce

@MichaelGFierce: Halozyme regrouping after ViroPharma trial flop. More from | Follow @MichaelGFierce

> Sequenom ($SQNM) won a clinical lab permit from the New York State Department of Health, only the second non-invasive prenatal test provider to do so after Illumina's ($ILMN) Verinata Health. More

> Cernostics has raised $1.4 million to develop a test to determine patients' risk of developing esophageal cancer. Story

> The New York Times takes an in-depth look at hip replacements around the world, charting pricing differences between the U.S. and Europe and the booming industry that built Zimmer ($ZMH), Biomet and other giants. Feature

> Alere ($ALR) is just two days away from a shareholder vote that could change the direction of the company, and management sent a final letter to investors urging them to elect its board nominees. Letter

> Life Technologies ($LIFE) has teamed up with RainTree Oncology Services to make the latest advances in molecular diagnostics more available to patients around the world. News

Biotech News

@FierceBiotech: Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII. News | Release | Follow @FierceBiotech

@JohnCFierce: India revokes divisional patents on Herceptin. These emerging markets sure can be quite nettlesome. Report | Follow @JohnCFierce

@RyanMFierce: Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More from FierceBiotechIT | Follow @RyanMFierce

> The FDA OKs 5 blockbusters in slow start to 2013 drug approvals. Report

> Bayer aims at hot cancer immunotherapy race with $540M R&D deal. News

Pharma News

@FiercePharma: Trending: Baxter fesses up to irregularities in China. Story | Follow @FiercePharma

@EricPFierce: ICYMI: Teva confronting tough time, sooner than later. Patent loss and soft quarter exemplify very real challenges. Article | Follow @EricPFierce

@CarlyHFierce: Roche signs agreement to make drug that prevents blindness in HIV patients available in developing nations. Release | Follow @CarlyHFierce

> J&J slapped with HHS subpoena on Nucynta marketing. Story

> India hits Roche's Herceptin in latest blow to Big Pharma patents. More

> Drug shortage complicates execution schedule for death penalty leader Texas. Article

CRO News

> Charles River boosts sales as charges drag profits. Article

> INC expands in Japan as local market soars. Story

> Clinipace reaches into the north with CRO partnership. Item

> Quintiles posts flat revenue as charges swallow profits. Report

> Covance swings to profit despite tough early-phase market. More

> KKR buying RPS, planning to merge it with PRA. Article

Biotech IT News

> China pharma R&D drives expanded use of Medidata software. News

> Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More

> Accelrys to ax 80 jobs after drop in quarterly profits. News

> Battle against breast cancer goes open source. Story

> Ex-Yahoo CEO backs genomics big data startup Bina. Article

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.